Special interest

Other antibiotic / bacterial infection experience

  • Cost-effectiveness model of a treatment for bacterial infections
  • Cost-effectiveness analysis model for Portugal on a treatment for bacterial infections
  • Cost-effectiveness analysis of a treatment of intra-abdominal infections in the USA
  • Assessment of the commercial and economic value for the development of new diagnostic tests for respiratory infections
  • HEOR team capabilities audit and training plan in infectious diseases
  • Literature review and development of a suite of dossiers in anti-infectives (antibacterial resistance)
  • Literature review of antibiotic resistance
  • Demonstrating the value of antibiotic resistance testing software
  • Development of a manuscript and consulting on economic evaluations alongside a clinical trial in intra-abdominal infections
  • Pharmacoeconomic and PRO design and analysis for an immunoglobulin product
  • Analysis in an EU study in primary immunodeficiency

Human papillomavirus (HPV)

  • Value cards for human papillomavirus (HPV)
  • Payer value deck and frequently asked questions for HPV and HPV-related diseases
  • Value pack for a HPV vaccine
  • Brief adaptation of a Markov model for a HPV vaccine
  • Update of a budget impact model for a HPV vaccine
  • Cost-effectiveness analysis of a HPV vaccine for Spain
  • HTA submission for a HPV vaccine
  • Manuscript on the German cost-effectiveness analysis of a HPV vaccine
  • Manuscript on the Spanish cost-effectiveness analysis of a HPV vaccine
  • Systematic literature review on the indirect protection from the HPV vaccination
  • Value demonstration and implementation plan for a new HPV test
  • Training sales reps on an interactive model for a HPV vaccine
  • Analysis and reporting on the budget impact of a HPV vaccine
  • One-pager communication tool on cross-protection in HPV
  • One-pager on HPV in head and neck cancer
  • Revision of one-pagers in HPV vaccines
  • Literature review of epidemiology and economic data in HPV
  • Update to European one-pager value communication tools for HPV and for a nine-valent HPV vaccine
  • e-v@luate platform for HPV vaccines
  • Update to a payer value deck in HPV infection
  • Evidence package (literature review and value messages) for HPV vaccination
  • Adaptation of a Markov model on a HPV vaccine to Belgium
  • Development of a rationale for the need for a HPV vaccine
  • Development of a PRO strategy in cervical cancer and HPV
  • Summary report, top-up literature review, meta-analysis, editorial board and manuscripts on HPV infection and cervical cancer

HPV vaccines

  • Value pack for a HPV vaccine
  • Payer value deck update for HPV
  • Literature review of epidemiology and economic data in HPV
  • Systematic literature review on the indirect protection from the HPV vaccination
  • HTA submission for a HPV vaccine
  • Cost-effectiveness analysis of a HPV vaccine for Spain
  • Manuscripts on the German and Spanish cost-effectiveness analysis of a HPV vaccine
  • Brief adaptation of a Markov model for a HPV vaccine
  • Update of a budget impact model for a HPV vaccine
  • Analysis and reporting on the budget impact of a HPV vaccine
  • Training sales reps on an interactive model for a HPV vaccine
  • Update to European one-pager value communication tool for a nine-valent HPV vaccine
  • One-pager communication tool on cross-protection in HPV
  • Revision of one-pagers in HPV vaccines
  • e-v@luate platform for HPV vaccines
  • e-v@luate EVIDENCE platform for HPV vaccines
  • Evidence package (literature review and value messages) for HPV vaccination
  • Development of a rationale for the need for a HPV vaccine

Human immunodeficiency virus (HIV) / Acquired immune deficiency syndrome (AIDS)

  • Business planning toolkit in HIV
  • Development of a payer value story in HIV
  • Payer value story briefing document in HIV
  • Review of an economic model for HIV and submission to the SMC
  • Budget impact model in HIV
  • Targeted literature review of adherence in HIV
  • Targeted literature review in HIV and inflammation
  • Targeted literature synthesis of viral blips and viremia in patients with HIV
  • Literature review on inflammation in patients with HIV
  • Consulting in a multinational case-control study: Impact of side effects on the quality of life (QoL) of HIV patients
  • Advisory board consultation regarding product status and development in HIV
  • General consultancy on PRO endpoints in HIV/AIDS trials
  • Recommendations for the inclusion of PROs into HIV trials
  • Development of an expert report and FDA meeting on tolerability in HIV
  • Consulting on the development of a PRO strategy for international HIV trials with interviews in the US and Puerto Rico
  • Consulting on study documents and development of SAP for psychometric validation of a PRO instrument of tolerability in patients with HIV
  • Preparation and development of a manuscript on HIV Patient Symptom Profile (HIV PSP)
  • Preliminary psychometric validation of the HIV PSP questionnaire using the UK SWITCH study data
  • Analysis of HIV PSP data from the SWITCH study to compare treatment arms
  • Confirming concept definitions of the HIV Treatment Tolerability Index for translation purposes
  • An evidence synthesis on the efficacy and safety of two drugs and protease inhibitors in treatment‑naïve HIV patients
  • Manuscript network meta-analysis of an antiretroviral drug for the treatment of HIV
  • Budget impact tool for an antiretroviral drug for treatment-naive HIV
  • Literature review of the epidemiology and burden of illness in HIV-related neuropathy
  • Top-up literature review, revised manuscript and presentations on HIV and AIDS
  • Development and psychometric validation of a PRO instrument of tolerability in patients with HIV
  • Two abstracts, two posters and a manuscript on the development and psychometric validation of a PRO instrument of tolerability in patients with HIV
  • Selection of PRO measures for HIV trials

Glioblastoma

  • Development of a global value dossier in the treatment of glioblastoma
  • AMCP dossier in glioblastoma multiforme
  • Early global value dossier in newly diagnosed glioblastoma
  • Clinical trial analyses to support health-related quality of life (HRQoL) in glioblastoma
  • Review of instruments for a glioblastoma trial and recommendation of a strategy
  • PRO dossier on glioblastomas for the EMA
  • Literature review on overall survival and progression-free survival in glioblastomas
  • Poster on the association of HRQoL and NCF with progression-free survival (PFS) and PD in glioblastoma
  • Indirect comparison of two treatments in 2nd line glioblastoma
  • Training slide deck for COAs in glioblastoma

Biosimilars

Endocrinology

  • Payer value slide deck for a biosimilar in diabetes
  • Budget impact models for a biosimilar in type 1 and type 2 diabetes mellitus
  • Global value dossier, AMCP and accompanying slide sets for an insulin biosimilar

Immunology

  • Payer value slides for immunology biosimilars
  • Frequently asked questions to support the introduction of a new biosimilar in immunology
  • Frequently asked questions for biosimilar policy in immunology
  • Frequently asked questions on an immunology biosimilar for rheumatoid arthritis
  • Budget impact model for a biosimilar
  • Literature review and update to budget impact model in an immunology biosimilar
  • Updates to a US budget impact model for an immunology biosimilar
  • Update to an AMCP dossier for an immunology biosimilar
  • Originator vs. biosimilar value proposition update in immunology
  • Updates to a global value dossier, AMCP dossier and budget impact model on a rheumatoid arthritis biosimilar

Musculoskeletal diseases

  • Value message testing for a biosimilar in rheumatoid arthritis
  • Budget impact model for a biosimilar in autoimmune disease

Oncology

  • Burden of disease deck and frequently asked questions deck in breast cancer biosimilars
  • Development of a cost-calculator for a biosimilar for breast and gastric cancer
  • One-pager communication in a breast cancer biosimilar
  • Payer value deck update for a breast cancer biosimilar
  • Response to payer questions update for a breast cancer biosimilar
  • Budget impact model for a biosimilar in HER2 breast cancer

Women’s health

  • Development of a value dossier, health economic model and literature review in an infertility biosimilar to support pricing and reimbursement submissions in 15 EU countries
  • Pricing updates in Europe for a biosimilar hormone treatment for female infertility

Other

  • Global value and reimbursement dossier for a biosimilar in autoimmune disease
  • Biosimilar payer communications in dermatology, gastroenterology and immunology
  • Global value dossiers and budget impact models for biosimilars in ankylosing spondylitis, Crohn’s disease, inflammatory bowel disease (IBD), osteoarthritis, psoriasis and rheumatoid arthritis
  • Manuscript on a budget impact model for a biosimilar in haematology and rheumatology

Phenylketonuria

  • Value dossier update for a treatment in phenylketonuria (PKU)
  • Updating of a cost manuscript for PKU
  • Value strategy, landscape analysis, health economic model and value dossier development for PKU
  • Development of a poster on a Delphi Panel in PKU
  • Measurement strategy consulting for endpoint hierarchy development in PKU
  • FDA briefing document to support a client’s phase III study measurement strategy in PKU
  • Outcomes interviews in PKU, resource use and impact on patients

Varicella

  • Update to payer value slide deck for varicella
  • Payer value deck for a varicella vaccine
  • Payer material development for vaccines in varicella
  • Response to payer questions deck in varicella
  • e-v@luate platform on vaccines for varicella

Pneumococcal vaccines

  • Manuscripts on the health economics of a pneumococcal vaccine
  • Manuscripts on a vaccine for pneumococcal disease
  • Payer communications on a vaccine for pneumococcal disease
  • Responses to payer questions update on a pneumococcal disease vaccine
  • Payer value deck update for a pneumococcal disease vaccine
  • Payer material development on a pneumococcal disease vaccine
  • Update to a one-page value proposition on a pneumococcal disease vaccine
  • e-v@luate platform on a pneumococcal disease vaccine

Pneumococcal disease

  • Manuscripts on the health economics of a pneumococcal vaccine
  • Manuscript on cost-effectiveness analysis in pneumococcal disease
  • Manuscripts on a vaccine for pneumococcal disease
  • Payer value deck for pneumococcal disease
  • Payer value deck update for a pneumococcal disease vaccine
  • Payer communications on pneumococcal disease
  • Payer communications on a vaccine for pneumococcal disease
  • Payer material development for vaccines in pneumococcal disease
  • Responses to payer questions update on a pneumococcal disease vaccine
  • Update to a one-page value proposition on a pneumococcal disease vaccine
  • e-v@luate platform on vaccines for pneumococcal disease

Other vaccines

  • One-pager value communication tool for the measles, mumps and rubella (MMR) vaccine
  • Development of an e-v@luate EVIDENCE platform for a vaccines portfolio
  • Payer material development for vaccines in hepatitis A, rotavirus gastroenteritis (RVGE), shingles and varicella
  • Payer value slides for a varicella vaccine
  • Payer value deck for an MMR and varicella vaccine
  • Payer communications on a herpes zoster vaccine
  • e-v@luate platform on vaccines for HPV, varicella, MMR, shingles, hepatitis A and rotavirus
  • Strategic consultancy on physician attitudes and preferences regarding adult vaccinations

Other orphan drugs and rare diseases

  • Presentation on the challenges and solutions of selecting and developing endpoints for use in paediatric populations and rare diseases
  • Measurement strategy to demonstrate efficacy of medical devices in patients with pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumour (dTGCT)

Medical Devices

Allergic conditions

  • Focus groups assessing patient experience with nasal spray in allergic rhinitis, analysis of results and development of a report on concept elicitation and cognitive debriefing
  • Validation of the preference module of the Experience with Allergic Rhinitis Nasal Spray Questionnaire (EARNS-Q)
  • Manuscript on the development of the EARNS-Q
  • Regulatory support for the EARNS-Q
  • Preference questionnaire on allergic rhinitis spray devices

Cardiovascular disease

  • Demonstrating the value of a transcatheter heart valve in aortic stenosis
  • Gap analysis of PRO measures to substantiate labelling claims in angina trials of a drug-eluting stent (DES)
  • Development and validation of patient and clinician tools for myocardial infarction imaging
  • Analysis and reporting of myocardial infarction imaging validation study data
  • Clinician and patient satisfaction in an observational study in myocardial infarction SPECT imaging
  • Validation of clinician and patient questionnaires for myocardial infarction imaging
  • Demonstrating the value of a transcatheter heart valve in aortic stenosis
  • General consulting on a new stent device
  • Report on the cost of diagnosing vascular diseases with an MRA as the primary imaging modality

Central nervous system/neurology

  • Advisory board for a clinical screening tool for overactive bladder in multiple sclerosis (MS)
  • Development and validation of a clinical screening tool for overactive bladder in MS
  • Validation of a brief series of questions with a subgroup of MS patients

Dermatology

  • Testing PRO measures in electronic devices for rosacea

Endocrinology and metabolic diseases

  • Development of a manuscript on patient perceptions of prefilled insulin delivery devices
  • Consultation on a market research study on patient perceptions of pre-filled insulin pens
  • Injection Pen Assessment Questionnaire (IPAQ) field study in growth hormone deficiency
  • Establishing support of content validity for the modified Injection Pen Assessment Questionnaire (IPAQ) in growth hormone deficiency
  • Development of an instrument to assess subject perception of two gastric bands in obesity

Gastrointestinal diseases

  • Development of a global value dossier and budget impact model for capsule endoscopy for colonoscopy
  • Global value dossier for a therapy device in refractory ascites
  • Translation to support development of a value dossier and budget impact model in capsule endoscopy for colonoscopy
  • Patient Assessment of Constipation Symptoms (PAC-SYM) and analysis of a skin patch containing an opioid pain medication
  • Managing patients with stoma: Adaptation of a Quality of Life Index (QLI) questionnaire to current needs for colostomy patients

Haematology

  • Development and testing of a novel web-based tool to evaluate patient preference for a reconstitution device for haemophilia A in a real-world setting

Immunology

  • Strategic consultancy on physician attitudes and preferences regarding adult vaccinations
  • Demonstrating the value of antibiotic resistance testing software
  • Measurement strategy to demonstrate efficacy of medical devices in patients with pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumour (dTGCT)

Infectious diseases

  • Systematic literature review on the indirect protection from the HPV vaccination
  • Value demonstration and implementation plan for a new HPV test
  • Value pack for a HPV vaccine
  • Training sales reps on an interactive model for a HPV vaccine
  • Update of a budget impact model for a HPV vaccine
  • Cost-effectiveness analysis of a HPV vaccine for Spain
  • HTA submission for a HPV vaccine
  • Manuscripts on the German and Spanish cost-effectiveness analysis of a HPV vaccine
  • Analysis and reporting on the budget impact of a HPV vaccine
  • Two manuscripts on an influenza vaccine for patients at risk and patients over 65 years old in France
  • Conference poster on the cost effectiveness of adjuvant influenza vaccination in France
  • Update of a value dossier on an influenza vaccine
  • Cost-effectiveness analysis of an influenza vaccine
  • Review of influenza vaccine uptake data
  • Updating an economic model of influenza vaccination (phase 1) – update of a model in patients aged over 65 years in France and the UK
  • Communications package for an influenza vaccine
  • Economic value dossiers for influenza vaccines in a) an unprimed paediatric population and b) a primed school age population (intranasal delivery) including literature review, gap analysis and recommendations
  • Economic evaluation of a workplace influenza vaccination in Russia
  • Communication of the economics of an influenza vaccine
  • Manuscripts on the health economics of a pneumococcal vaccine
  • Brief adaptation of a Markov model for a HPV vaccine
  • Adaptation of a Markov model on a HPV vaccine to Belgium
  • Development of a rationale for the need for a HPV vaccine
  • Communications package for an influenza vaccine
  • Adaptation of an influenza vaccine model to Belgium
  • Regulatory support for the validation of a questionnaire for influenza vaccination

Oncology

  • Cognitive debriefing interviews to assess usability of an ePRO device for use in forthcoming clinical trials in ovarian cancer

Ophthalmology

  • Formal recommendations on a regulatory briefing document for intraocular cataract lenses
  • Development of a PRO questionnaire to assess implantation of an intraocular lens in cataract patients
  • Cognitive interviews for the development of a PRO to assess intraocular lenses in cataract patients
  • Scientific dissemination of the patient-reported intraocular lens questionnaire
  • Etiology and meta-analysis of posterior cacular opacification comparing two lens types
  • Support on the intraocular cataract lenses (IOL) Expert Focus Group
  • Manuscript on HRQoL trial results of a new lens

Respiratory system

  • Global value dossier update and e-v@luate upload for an asthma device
  • Value proposition for a new metered dose inhaler to treat chronic obstructive pulmonary disease (COPD)
  • Structured literature review and qualitative interviews with payers/HCPs on a device for COPD
  • Development of a mini global value dossier for an asthma device
  • Structured literature reviews for paediatric wheeze detection
  • Rapid structured literature review of nebulisation inhalation efficiency in paediatric asthma and other respiratory conditions
  • Validation of the preference module of the Experience with Allergic Rhinitis Nasal Spray Questionnaire (EARNS-Q)
  • Manuscript on the development of the EARNS-Q
  • Focus groups assessing patient experience with nasal spray in allergic rhinitis, analysis of results and development of a report on concept elicitation and cognitive debriefing
  • Regulatory support for the EARNS-Q
  • Preference questionnaire on allergic rhinitis spray devices
  • Update to the pilot inference model for an inhaler used in the treatment of asthma
  • PRO strategy support for an inhaler treatment for COPD
  • Exit interviews on a connected inhaler system for asthma

Surgery and wound care

  • Training in a manual compression device for surgery
  • Strategic review of European market access potential for a surgical device
  • Value demonstration on a new wound care technology and the cost of pain management, allowing data to be tailored for local markets and local payers
  • AMCP dossiers for several surgical products
  • Identification of data inputs for a Canadian budget impact model in surgery

Urology and urogenital diseases

  • Systematic review of lithotripters for ureterolithiasis

Women’s health

  • Manuscript publication on a monthly contraceptive device
  • Modification, development and validation of an existing tool in order to explore satisfaction and tolerability for an intrauterine device (IUD) versus oral contraceptives
  • Modification of the EVAPIL-R in order to explore tolerability for an intrauterine system (IUS) versus an implantable contraceptive

Other

  • Value strategy training on access to medical devices
  • Panel and presentation on PRO research on medical devices

Polio

  • Burden of disease literature review on polio in the UK and Ireland

Ear infections and acute otitis media

  • Diary of a caregiver validation for ear infection using the standard methodology
  • Training and manuscripts on the acute otitis media caregiver diary
  • Quality of life impact of otitis media and associated productivity loss in Malaysia and South Korea

Hepatitis

Hepatitis A

  • Update to payer value deck in Hepatitis A
  • Payer material development for vaccines in hepatitis A
  • e-v@luate platform on vaccines for hepatitis A
  • Burden of disease literature review on hepatitis A in the UK and Ireland

Hepatitis B

  • Systematic literature review of a treatment for chronic hepatitis B
  • Preparation of a NICE submission for a hepatitis B drug
  • SMC submission for a treatment for chronic hepatitis B
  • Database analysis to calculate the economic burden of hepatitis B in the UK

Hepatitis C

  • Therapeutic area strategy analysis and reporting in chronic hepatitis C virus
  • Biomarkers in the treatment of hepatitis C virus infected patients – personalised medicine
  • Maximizing the use of a treatment for hepatitis C-infected patients through personalised medicine – extending the tool to additional treatments
  • Treatment algorithm for hepatitis C treatment
  • One-pager value communication tool for Hepatitis C
  • Comprehensive literature research in chronic hepatitis C in Asian countries
  • Database development and analysis in hepatitis C
  • Concept elicitation and cognitive debriefing interviews with hepatitis C patients in multiple countries
  • Development of an EMA summary document for several instruments used in hepatitis C trials
  • Development of a PRO outcomes summary document and communications support in hepatitis C trials
  • Description, interpretation and analysis of pooled data related to the use of several questionnaires, scales and screening tests in three hepatitis C clinical trials
  • Conceptual model for patients with hepatitis C
  • Psychometric validation of a hepatitis C symptom checklist using phase III trial data
  • Treatment patterns, healthcare utilization and costs associated with the hepatitis C virus in Japan
  • Selection of PRO measures for hepatitis C trials

Typhoid

  • Burden of disease literature review on typhoid in the UK and Ireland

Yellow fever

  • Burden of disease literature review on yellow fever in the UK and Ireland

Rabies

  • Burden of disease literature review on rabies in the UK and Ireland